Michelle Nanjad

Midway Pharmaceuticals, Inc. develops non-antibiotic therapies. It capitalizes on the finding the molecular weight polymers, taken orally but not systemically absorbed, can inhibit the pathogenic behavior of bacteria in the GI tract, enhance gut barrier function and promote gastrointestinal healing. The company was founded by John Alverdy, Eugene Chang and Elaine Petrof in 2005 and is headquartered in Spring House, PA.

Voyager Capital LLC (Voyager Capital) is a venture capital firm founded in 1997 by Enrique Godreau, William H. McAleer and Tony Audino. The firm is headquartered in Seattle, Washington.

Chaordix, Inc. provides crowdsourcing technology solutions. It focuses on developing those companies which emerged from crowdsourced discoveries. The firm portfolio includes Gwabs, FilmRiot and the Chaordix crowdsourcing platform. The company was founded by Michael J. Sikorsky and Shelley Kuipers in 2006 and is headquartered in Calgary, Canada.

Part of Fortive Corp., Accruent North ULC is a Canadian company that provides online construction project management solutions. The company is based in Calgary, Canada. The company was founded by Alice Reimer. Accruent North ULC was acquired by Accruent LLC, part of Fortive Corp. from September 11, 2018 on December 07, 2012.

Calgary Economic Development provides economic development through attraction of business investments, trades, and increasing workforce. It offers business abroad, trade missions, and workforce management. The company is headquartered in Calgary, Canada.

Cambrian House, Inc. provides managed crowdsourcing communities. It offers a software platform, an enterprise-class crowdsourcing engine that enables users to configure a crowdsourcing site to address crowdsourcing needs in organizations. The company was founded by Shelley Kuipers in 2006 and is headquartered in Calgary, Canada.

Atrin Pharmaceuticals LLC engages in discovery and development of proprietary medications. It offers ATRN-502, a p53 activator; and ATRN-507, a dual ligand showing specificity and selectivity against cancer cells. The firm also provides Atrize, a platform that offers phenotypic FACS-based screening that is applicable across R&D, clinical applications, and a tool for personalized medicine. The company was founded by Oren Gilad and Kevin D. Smith in 2011 and is headquartered in Doylestown, PA.

RxMP Therapeutics, Inc. develops and designs novel hemostatic agents to arrest or prevent excessive bleeding. The company is headquartered in Miami, FL.

Virion Therapeutics LLC develops chronic viral disease vaccines. It offers ChiVax and ChiVax-gD vaccines. The firm engages in developing immune-based treatments for virally-associated cancers and chronic viral infections. The company was founded by Bernard C. Rudnick, Hildegund C. J. Ertl and Andrew D. Luber in 2018 and is headquartered in Newark, DE.

The51 Ventures, Inc. (The51 Ventures) is a venture capital firm founded in 2019 by Judy Fairburn, Shelly Kuipers, and Alice Reimer. The firm is headquartered in Calgary, Alberta.

Fillip Fleet, Inc. is the world's first digital fuel card program designed for small business fleets. The company is based in Calgary, CA. The Canadian company provides business owners with the ability to issue cards to their drivers, who can use the smartphone app to pay at any fuel station using a tap-to-pay card reader. and has subsidiaries in the United States. The company was founded by Alice Reimer, who has been the CEO since incorporation.

SIRPant Immunotherapeutics, Inc. is a clinical-stage immuno-oncology company based in Hummelstown, PA. The company specializes in developing next-generation macrophage-based immunotherapies for the treatment of hematological malignancies and solid tumors. The cell therapy technology employed by SIRPant is based on the reduction of SIRP? expression combined with activation of the patient's own macrophages. This population of SIRP?low activated macrophages is designed to attack the tumor following injection by activating the patient's immune system to produce broad-spectrum anti-tumor activity that utilizes patient T-cells and antibodies targeting cancer neoantigens. The company was founded by Richard F. Fitzgerald, and the CEO is Robert J. Towarnicki.

Founded in 2012, Atrin Pharmaceuticals, Inc. is a DNA Damage Response development company that focuses on a pipeline of products resulting from a series of novel conformationally restricted macrocyclic molecules. Part of Aprea Therapeutics, Inc., the company is based in Doylestown, PA. Atrin Pharmaceuticals was acquired by Aprea Therapeutics, Inc. on May 16, 2022 for $1.33 million. The company's products have the highest known potency for inhibiting ATR and exhibit ATR selectivity with potential broad therapeutic profile.